Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Sera Prognostics Inc

Healthcare US SERA

1.84USD
-0.01(0.54%)

Last update at 2026-06-23T20:00:00Z

Day Range

1.841.85
LowHigh

52 Week Range

1.5212.36
LowHigh

Fundamentals

  • Previous Close 1.85
  • Market Cap281.15M
  • Volume22465
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-36.71300M
  • Revenue TTM0.21M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 0.07M
  • Diluted EPS TTM-1.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -44.18600M -35.00900M -19.84800M -16.52100M
Minority interest - - - -
Net income -44.24700M -36.22800M -21.60700M -20.43900M
Selling general administrative 16.78M 14.09M 6.56M 4.28M
Selling and marketing expenses 14.70M 10.33M 3.65M 2.96M
Gross profit 0.07M 0.04M 0.01M 0.02M
Reconciled depreciation 0.76M 0.66M 0.90M 0.95M
Ebit -45.65200M -35.39500M -17.97100M -16.55900M
Ebitda -44.12500M -34.26300M -17.11400M -13.60300M
Depreciation and amortization 1.53M 1.13M 0.86M 2.96M
Non operating income net other 1.53M 1.13M - -
Operating income -45.65200M -35.39500M -17.97100M -16.55900M
Other operating expenses 45.92M 35.48M 18.00M 16.59M
Interest expense 0.06M 0.75M 1.84M 1.97M
Tax provision - - - -
Interest income 0.46M 0.14M 0.04M 0.06M
Net interest income 0.40M -0.74600M -1.79700M -1.90800M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.06M 1.22M 1.76M 3.92M
Total revenue 0.27M 0.08M 0.03M 0.04M
Total operating expenses 45.73M 35.44M 17.98M 16.58M
Cost of revenue 0.19M 0.04M 0.01M 0.02M
Total other income expense net 1.47M 0.39M -1.87700M 0.04M
Discontinued operations - - - -
Net income from continuing ops -44.12500M -34.26300M -19.84800M -16.52100M
Net income applicable to common shares -44.18600M -35.00900M -19.84800M -16.52100M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 95.44M 116.33M 147.03M 14.80M 23.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.80M 1.31M 1.99M 0.20M 0.16M
Total liab 25.28M 17.39M 8.46M 140.37M 129.88M
Total stockholder equity 70.16M 98.94M 138.56M -125.57000M -106.62400M
Deferred long term liab - - - 0.03M -
Other current liab 2.14M 4.44M 4.02M 0.19M 0.18M
Common stock 0.00300M 0.00300M 0.00300M - -
Capital stock 0.00300M 0.00300M 0.00300M 0.00000M 0.00000M
Retained earnings -246.89600M -210.65400M -166.46800M -131.45900M -111.61100M
Other liab - - - 0.14M 0.82M
Good will - - - - -
Other assets - - 0.16M 0.10M 0.07M
Cash 3.88M 29.88M 58.93M 13.53M 21.39M
Cash and equivalents - - - - -
Total current liabilities 24.44M 15.54M 8.41M 11.24M 5.90M
Current deferred revenue 20.23M 9.08M 3.12M 2.41M 1.24M
Net debt -2.02200M -27.56600M -58.80400M -4.86000M -12.07500M
Short term debt 1.02M 0.46M 0.07M 8.20M 3.74M
Short long term debt - - - 8.13M 3.67M
Short long term debt total 1.86M 2.31M 0.13M 8.67M 9.31M
Other stockholder equity 317.07M 310.57M 158.18M 5.89M 4.99M
Property plant equipment - - 1.77M 0.96M 1.64M
Total current assets 61.34M 90.12M 110.25M 13.73M 21.55M
Long term investments 30.84M 21.33M 34.85M - -
Net tangible assets - 98.94M 138.56M -125.57000M -106.62400M
Short term investments 45.20M 52.83M 46.18M - -
Net receivables 11.47M 6.11M 3.14M 0.00200M 0.00100M
Long term debt - - - 0.35M 5.44M
Inventory - - - - -
Accounts payable 1.05M 1.55M 1.20M 0.44M 0.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01500M -0.98100M -0.18300M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00300M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -210.65400M -166.46800M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 1.82M 0.16M 0.10M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 34.10M 26.20M 36.78M 1.06M 1.71M
Capital lease obligations 1.86M 2.83M 0.13M 0.20M 0.21M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 6.33M -81.25500M -0.14900M -0.00600M
Change to liabilities -0.16200M 1.99M -0.30700M -0.53400M
Total cashflows from investing activities 5.55M -82.55900M -0.14900M -0.00600M
Net borrowings -0.30300M -7.66400M -1.70200M 2.98M
Total cash from financing activities 0.00500M 159.59M 9.16M 33.05M
Change to operating activities -2.68000M -3.73800M -0.00200M -3.11800M
Net income -44.18600M -35.00900M -19.84800M -16.52100M
Change in cash -29.05400M 45.40M -7.85700M 13.72M
Begin period cash flow 58.93M 13.53M 21.39M 7.67M
End period cash flow 29.88M 58.93M 13.53M 21.39M
Total cash from operating activities -34.61000M -31.63600M -16.86800M -19.32400M
Issuance of capital stock 0.00000M 165.59M 10.69M 30.05M
Depreciation 0.76M 0.66M 0.90M 0.95M
Other cashflows from investing activities 0.02M - - -
Dividends paid - - - -
Change to inventory - -3.60800M 0.11M -3.02000M
Change to account receivables -0.08600M -0.02500M -0.00200M 0.00600M
Sale purchase of stock 0.31M 167.26M - -
Other cashflows from financing activities 5.55M 100.65M 11.91M 35.76M
Change to netincome 4.81M 2.76M 2.40M -0.10300M
Capital expenditures 0.79M 1.30M 0.15M 0.11M
Change receivables -2.97000M -3.14100M - -
Cash flows other operating 7.15M 1.11M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -29.05400M 45.40M - -
Change in working capital 3.55M -0.04400M -0.31100M -3.64600M
Stock based compensation 5.05M 3.13M 0.73M 0.44M
Other non cash items 0.21M 0.68M 1.67M -0.43800M
Free cash flow -35.40100M -32.94000M -17.01700M -19.43300M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SERA
Sera Prognostics Inc		 -0.01 0.54% 1.84 - - 1023.63 4.46 869.32 -7.5385
TMO
Thermo Fisher Scientific Inc		 5.34 1.15% 469.35 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 0.78 0.44% 178.97 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 0.18 0.14% 126.67 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -4.42 0.81% 541.31 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc

2749 East Parleys Way, Salt Lake City, UT, United States, 84109

Key Executives

Name Title Year Born
Dr. Gregory C. Critchfield M.D., M.S. Exec. Chairman, CEO & Pres 1953
Mr. Robert G. Harrison Chief Information Officer 1966
Mr. Benjamin G. Jackson J.D. Gen. Counsel 1980
Dr. Steven W. Graves Co-Founder and Co-Chairman of The Scientific Advisory Board NA
Dr. M. Sean Esplin M.D. Co-Founder and Co-Chairman of Scientific Advisory Board NA
Mr. Jay M. Moyes M.B.A., MBA Chief Financial Officer 1954
Dr. John J. Boniface Ph.D. Chief Scientific Officer 1963
Ms. Nadia F. Altomare Chief Commercial Officer 1971
Dr. Paul Kearney Ph.D. Chief Data Officer 1968
Dr. Michael R. Foley M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.